New research from the University of Queensland has shown for the first time that visual hallucinations in people with macular degeneration are associated with abnormally heightened activity in the visual cortex of the brain.

The findings, published in the journal Current Biology, could improve the diagnosis of such hallucinations.

Macular degeneration is a retinal eye disease that causes progressive deterioration of the central region of the retina, leading to a visual loss in the center of the field of vision, while peripheral vision usually remains unaffected. In Australia, MD is the leading cause of legal blindness in people over the age of 40.

Curiously, many people who develop MD go on to develop a condition known as Charles Bonnet Syndrome, in which they experience hallucinations as the brain adjusts to significant vision loss. The hallucinations can be simple geometric patterns, or much more complex scenes involving animals, people, and places.

Why some people with MD experience hallucinations, while others do not, has remained unclear, but there have been suggestions that the activity levels – or ‘excitability’ – of certain visual regions of the brain could play a role.

To address this, Professor Jason Mattingley and his team from The University’s Queensland Brain Institute and School of Psychology stimulated the peripheral visual fields of study participants and found that individuals with hallucinations do indeed show significantly heightened activity in particular parts of their visual system.

“We used electroencephalography (EEG) to measure brain electrical activity in three groups: a group with macular degeneration and Charles Bonnet hallucinations, a group with macular degeneration and no hallucinations, and a control group of visually-healthy elderly people,” Dr. David Painter – the paper’s first author – said.

“Their task was to look at letters appearing on the screen in their periphery, and we flashed checkerboards at unique frequencies on the screen.

“We found that these checkerboards produced unique oscillations in visual areas of the brain that we can measure using mathematical techniques.

“The main finding is that when we drive activity in the visual system of people with macular degeneration who report experiencing hallucinations, there is a huge visual response compared with participants who have the same visual loss but don’t have the hallucinations.”

Dr. Painter noted that while people with macular degeneration who experience hallucinations demonstrated visual hyperexcitability, the translation of this hyperexcitability into hallucinations was not automatic and is dependent on external triggers which are still not known.

“During the testing, none of our participants experienced hallucinations, so it’s not that heightened excitability of the brain produces hallucinations – it’s some other factor,” Dr. Painter said.

“Sometimes people have these hallucinations when they’re in periods of low sensory stimulation, such as in low-light or periods of inactivity, but for others, it can be triggered by things such as car rides or television – it varies for the individual.”

“What our results say is that the brains of those reporting hallucinations are more excitable, but it still remains unclear how that excitability is then translated into hallucinations – that’s a question for future research.”

The findings could help reduce misdiagnosis of hallucinations in people with MD.

“When people get older and they start having these unusual experiences, they are often worried that something is wrong with them, such as dementia or something similar, so they tend to not report the hallucinations for fear they may be treated differently,” Dr. Painter said.

“Doctors sometimes don’t recognize the disease either, and therefore can give people inappropriate medication, but our method potentially allows us to detect people who might have Charles Bonnet Syndrome by looking at their brain excitability in response to flickering stimuli.”

“Once people realize it’s not a brain disorder as such, they tend to have a neutral or even positive experience of their hallucinations. Unlike the hallucinations in people with schizophrenia, for example, individuals with Charles Bonnet Syndrome are aware their hallucinations aren’t real.”

###